论文部分内容阅读
研究背景及临床问题伴有肾功能不全的患者使用新型口服抗凝药时应进行剂量调整。以达比加群酯为例,根据药品说明书,达比加群酯的常规剂量为150 mg bid,中度肾功能不全(CrC L 30~50mL·min-1)的患者应使用低剂量达比加群酯110 mg bid。如果有需要减量的情况而未进行剂量调整,则可能增加房颤患者的出血风险;反之,若无
Study Background and Clinical Problems Patients with renal insufficiency should be given dose adjustments when using new oral anticoagulants. In the case of dabigatran etexilate, the usual dabigatran etexilate is 150 mg bid according to the manufacturer’s instructions. Patients with moderate renal insufficiency (CrC L 30 - 50 mL · min-1) should receive low-dose dabigatran Add Group Ester 110 mg bid. If there is a need to reduce the situation without dose adjustment, it may increase the risk of bleeding in patients with AF; the other hand, if not